NASDAQ:FEMY - Nasdaq - US31447E1055 - Common Stock - Currency: USD
1.16
-0.01 (-0.85%)
The current stock price of FEMY is 1.16 USD. In the past month the price decreased by -6.4%. In the past year, price decreased by -9.3%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.15 | 225.11B | ||
ISRG | INTUITIVE SURGICAL INC | 66.25 | 181.33B | ||
BSX | BOSTON SCIENTIFIC CORP | 37.75 | 150.75B | ||
SYK | STRYKER CORP | 30.5 | 141.91B | ||
MDT | MEDTRONIC PLC | 15.83 | 108.41B | ||
BDX | BECTON DICKINSON AND CO | 14.83 | 59.24B | ||
EW | EDWARDS LIFESCIENCES CORP | 29.27 | 44.75B | ||
IDXX | IDEXX LABORATORIES INC | 38.28 | 34.90B | ||
RMD | RESMED INC | 25.74 | 34.32B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.89 | 32.66B | ||
DXCM | DEXCOM INC | 42.61 | 27.57B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 15.88 | 23.58B |
Femasys, Inc. is a biomedical company, which engages in the development of novel solutions for reproductive healthcare. The company is headquartered in Suwanee, Georgia and currently employs 69 full-time employees. The company went IPO on 2021-06-18. The firm is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The firm has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. The company also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
FEMASYS INC
3950 Johns Creek Court, Suite 100
Suwanee GEORGIA US
CEO: Kathy Lee-Sepsick
Employees: 33
Company Website: https://www.femasys.com/
Investor Relations: https://ir.femasys.com/
Phone: 17705003910
The current stock price of FEMY is 1.16 USD. The price decreased by -0.85% in the last trading session.
The exchange symbol of FEMASYS INC is FEMY and it is listed on the Nasdaq exchange.
FEMY stock is listed on the Nasdaq exchange.
10 analysts have analysed FEMY and the average price target is 8.84 USD. This implies a price increase of 662.07% is expected in the next year compared to the current price of 1.16. Check the FEMASYS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
FEMASYS INC (FEMY) has a market capitalization of 31.49M USD. This makes FEMY a Nano Cap stock.
FEMASYS INC (FEMY) currently has 33 employees.
FEMASYS INC (FEMY) has a support level at 1.13 and a resistance level at 1.17. Check the full technical report for a detailed analysis of FEMY support and resistance levels.
The Revenue of FEMASYS INC (FEMY) is expected to grow by 222.54% in the next year. Check the estimates tab for more information on the FEMY EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
FEMY does not pay a dividend.
FEMASYS INC (FEMY) will report earnings on 2025-05-08.
FEMASYS INC (FEMY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.85).
The outstanding short interest for FEMASYS INC (FEMY) is 3.57% of its float. Check the ownership tab for more information on the FEMY short interest.
ChartMill assigns a technical rating of 1 / 10 to FEMY. When comparing the yearly performance of all stocks, FEMY turns out to be only a medium performer in the overall market: it outperformed 41.86% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to FEMY. Both the profitability and financial health of FEMY have multiple concerns.
Over the last trailing twelve months FEMY reported a non-GAAP Earnings per Share(EPS) of -0.85. The EPS increased by 7.61% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -151.2% | ||
ROE | -816.56% | ||
Debt/Equity | 2.35 |
ChartMill assigns a Buy % Consensus number of 82% to FEMY. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 41.2% and a revenue growth 222.54% for FEMY